Shenqi Yanshen Formula (SQYSF) protects against chronic kidney disease by modulating gut microbiota

References

• Qin Y, Tang H, Yan G, et al. A high triglyceride-glucose index is associated with contrast-induced acute kidney injury in Chinese patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020;11:522883.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• McCormick N, Zhang Y, Choi HK. Allopurinol and chronic kidney disease. N Engl J Med. 2020;383(17):1689–1690.
   PubMed Web of Science ®Google Scholar
• Moraes C, Borges NA, Mafra D. Resistant starch for modulation of gut microbiota: promising adjuvant therapy for chronic kidney disease patients? Eur J Nutr. 2016;55(5):1813–1821.
   PubMed Web of Science ®Google Scholar
• Esgalhado M, Borges NA, Mafra D. Could physical exercise help modulate the gut microbiota in chronic kidney disease? Future Microbiol. 2016;11:699–707.
   PubMed Web of Science ®Google Scholar
• Ren Z, Fan Y, Li A, et al. Alterations of the human gut microbiome in chronic kidney disease. Adv Sci (Weinh). 2020;7(20):2001936.
   PubMedGoogle Scholar
• Armani RG, Ramezani A, Yasir A, et al. Gut microbiome in chronic kidney disease. Curr Hypertens Rep. 2017;19(4):29.
   PubMed Web of Science ®Google Scholar
• End chronic kidney disease neglect. Nature. 2020;579(7798):173.
   Web of Science ®Google Scholar
• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252.
   PubMed Web of Science ®Google Scholar
• Allison SJ. Finerenone in chronic kidney disease. Nat Rev Nephrol. 2021;17(1):13.
   PubMed Web of Science ®Google Scholar
• Ying L, Tai-jun Z, Hong L, et al. Clinical observation on patients with chronic kidney disease stage 3-5 treated by the Chinese herbs formula of shenqiyanshenfang. China Med Guide. 2019;17(13):1–2.
   Google Scholar
• Bo L. Observation on the effect of shenqi yanshen decoction in adjuvant treatment of early chronic kidney disease. China Rural Med. 2021;28(6):45–46.
   Google Scholar
• G LD, M Z, Y GH. Rehmanniae radix and rehmanniae radix praeparata ameliorates renal interstitial fibrosis induced by unilateral ureteral occlusion in rats and their mechanism. Zhong Yao Cai. 2015;38(12):2507–2510.
   PubMedGoogle Scholar
• Zeng O, Li F, Li Y, et al. Effect of novel gasotransmitter hydrogen sulfide on renal fibrosis and connexins expression in diabetic rats. Bioengineered. 2016;7(5):314–320.
   PubMed Web of Science ®Google Scholar
• Xuan Y, Ding D, Xuan W, et al. A traditional Chinese medicine compound (Jian Er) for presbycusis in a mouse model: reduction of apoptosis and protection of cochlear sensorineural cells and hearing. Int J Herb Med. 2018;6(6):127–135.
   PubMedGoogle Scholar
• Liao H, Hu L, Cheng X, et al. Are the therapeutic effects of Huangqi (Astragalus membranaceus) on diabetic nephropathy correlated with its regulation of macrophage iNOS activity? J Immunol Res. 2017;2017:3780572.
   PubMed Web of Science ®Google Scholar
• Sham TT, Chan CO, Wang YH, et al. A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect. Biomed Res Int. 2014;2014:925302.
   PubMed Web of Science ®Google Scholar
• Wu J, Li W, Ye B, et al. The efficacy and safety of Xianling Gubao capsules in the treatment of knee osteoarthritis: a protocol for a randomized, double-blind, controlled trial. Medicine (Baltimore). 2021;100(36):e27086.
   PubMed Web of Science ®Google Scholar
• Guo M, Liu Y, Shi D. Cardiovascular actions and therapeutic potential of tetramethylpyrazine (Active component isolated from rhizoma chuanxiong): roles and mechanisms. Biomed Res Int. 2016;2016:2430329.
   PubMed Web of Science ®Google Scholar
• Hu Z, Gao L, Li C, et al. Efficacy of Longdan Xiegan decoction on the treatment of eczema: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2021;2021:8836117.
   PubMed Web of Science ®Google Scholar
• Lee BC, Choi JB, Cho HJ, et al. Rehmannia glutinosa ameliorates the progressive renal failure induced by 5/6 nephrectomy. J Ethnopharmacol. 2009;122(1):131–135.
   PubMed Web of Science ®Google Scholar
• Dong Q, Qiu LL, Zhang CE, et al. Identification of compounds in an anti-fibrosis Chinese medicine (Fufang Biejia Ruangan Pill) and its absorbed components in rat biofluids and liver by UPLC-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1026:145–151.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mao X, Chen W, et al. A discovery of clinically approved formula FBRP for repositioning to treat HCC by inhibiting PI3K/AKT/NF-κB activation. Mol Ther Nucleic Acids. 2020;19:890–904.
   PubMedGoogle Scholar
• Chan GCW, Wu HJ, Chan KW, et al. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice. Nephrology (Carlton). 2018;23(4):297–307.
   PubMed Web of Science ®Google Scholar
• Rasool MF, Ali S, Khalid S, et al. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases. Sci Rep. 2021;11(1):8589.
   PubMed Web of Science ®Google Scholar
• Sonfack CS, Nguelefack-Mbuyo EP, Kojom JJ, et al. The aqueous extract from the stem bark of garcinia lucida vesque (Clusiaceae) exhibits cardioprotective and nephroprotective effects in adenine-induced chronic kidney disease in rats. Evid Based Complement Alternat Med. 2021;2021:5581041.
   PubMed Web of Science ®Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31.
   PubMedGoogle Scholar
• Mandai S, Mori T, Nomura N, et al. WNK1 regulates skeletal muscle cell hypertrophy by modulating the nuclear localization and transcriptional activity of FOXO4. Sci Rep. 2018;8(1):9101.
   PubMed Web of Science ®Google Scholar
• Mazumder MK, Paul R, Bhattacharya P, et al. Neurological sequel of chronic kidney disease: from diminished Acetylcholinesterase activity to mitochondrial dysfunctions, oxidative stress and inflammation in mice brain. Sci Rep. 2019;9(1):3097.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhao Y, Zhong P, et al. EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress. Oncotarget. 2017;8(20):32655–32667.
   PubMedGoogle Scholar
• Yao H, Chi X, Jin Y, et al. Dexmedetomidine inhibits TLR4/NF-κB activation and reduces acute kidney injury after orthotopic autologous liver transplantation in rats. Sci Rep. 2015;5:16849.
   PubMed Web of Science ®Google Scholar
• Pereira NS, Queiroga TBD, Nunes DF, et al. Innate immune receptors over expression correlate with chronic chagasic cardiomyopathy and digestive damage in patients. PLoS Negl Trop Dis. 2018;12(7):e0006589.
   PubMed Web of Science ®Google Scholar
• An L, Feng F. Network pharmacology-based antioxidant effect study of zhi-zi-da-huang decoction for alcoholic liver disease. Evid Based Complement Alternat Med. 2015;2015:492470.
   PubMed Web of Science ®Google Scholar
• Hobby GP, Karaduta O, Dusio GF, et al. Chronic kidney disease and the gut microbiome. Am J Physiol Renal Physiol. 2019;316(6):F1211–f1217.
   PubMed Web of Science ®Google Scholar
• Meijers B, Evenepoel P, Anders HJ. Intestinal microbiome and fitness in kidney disease. Nat Rev Nephrol. 2019;15(9):531–545.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16(3):137–154.
   PubMed Web of Science ®Google Scholar
• Felizardo RJF, Watanabe IKM, Dardi P, et al. The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids. Pharmacol Res. 2019;141:366–377.
   PubMed Web of Science ®Google Scholar
• Sueyoshi M, Fukunaga M, Mei M, et al. Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin Exp Nephrol. 2019;23(7):908–919.
   PubMed Web of Science ®Google Scholar
• Meijers B, Farré R, Dejongh S, et al. Intestinal barrier function in chronic kidney disease. Toxins (Basel). 2018;10(7):298.
   PubMed Web of Science ®Google Scholar
• Sircana A, De Michieli F, Parente R, et al. Gut microbiota, hypertension and chronic kidney disease: recent advances. Pharmacol Res. 2019;144:390–408.
   PubMed Web of Science ®Google Scholar
• Ruszkowski J, Witkowski JM. Lactulose: patient- and dose-dependent prebiotic properties in humans. Anaerobe. 2019;59:100–106.
   PubMed Web of Science ®Google Scholar
• Arias N, Arboleya S, Allison J, et al. The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases. Nutrients. 2020;12(8):2340.
   PubMed Web of Science ®Google Scholar
• Glorieux G, Gryp T, Perna A. Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease. Toxins (Basel). 2020;12(4):245.
   PubMed Web of Science ®Google Scholar
• Hu Q, Wu K, Pan W, et al. Intestinal flora alterations in patients with early chronic kidney disease: a case-control study among the Han population in southwestern China. J Int Med Res. 2020;48(6):300060520926033.
   PubMed Web of Science ®Google Scholar
• Konrad L, Andersen K, Kesper MS, et al. The gut flora modulates intestinal barrier integrity but not progression of chronic kidney disease in hyperoxaluria-related nephrocalcinosis. Nephrol Dialysis Transplantation. 2019;35(1):86–97.
   Web of Science ®Google Scholar
• Jiang S, Wang B, Sha T, et al. Changes in the intestinal microbiota in patients with stage 5 chronic kidney disease on a low-protein diet and the effects of human to rat fecal microbiota transplantation. Med Sci Monit. 2020;26:e921557.
   PubMed Web of Science ®Google Scholar
• Hanifi GR, Samadi Kafil H, Tayebi Khosroshahi H, et al. Bifidobacteriaceae family diversity in gut microbiota of patients with renal failure. Arch Razi Inst. 2021;76(3):521–528.
   PubMedGoogle Scholar
• Wu IW, Lin CY, Chang LC, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. Int J Biol Sci. 2020;16(3):420–434.
   PubMed Web of Science ®Google Scholar
• He LX, Abdolmaleky HM, Yin S, et al. Dietary fermented soy extract and oligo-lactic acid alleviate chronic kidney disease in mice via inhibition of inflammation and modulation of gut microbiota. Nutrients. 2020;12(8):2376.
   PubMed Web of Science ®Google Scholar
• Lun H, Yang W, Zhao S, et al. Altered gut microbiota and microbial biomarkers associated with chronic kidney disease. Microbiologyopen. 2019;8(4):e00678.
   PubMed Web of Science ®Google Scholar
• Lin TY, Wu PH, Lin YT, et al. Gut dysbiosis and mortality in hemodialysis patients. NPJ Biofilms Microbiomes. 2021;7(1):20.
   PubMed Web of Science ®Google Scholar
• Bhowmick UD, Bhattacharjee S. Bacteriological, clinical and virulence aspects of aeromonas-associated diseases in humans. Pol J Microbiol. 2018;67(2):137–149.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu K, Jin C. Clinical value of microRNA-378a-3p in sepsis and its role in sepsis-induced inflammation and cardiac dysfunction. Bioengineered. 2021;12(1):8496–8504.
   PubMed Web of Science ®Google Scholar
• Lee TH, Park D, Kim YJ, et al. Lactobacillus salivarius BP121 prevents cisplatin induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and pcresol sulfate via alleviating dysbiosis. Int J Mol Med. 2020;45(4):1130–1140.
   PubMed Web of Science ®Google Scholar
• Lakshmanan AP, Al Za’abi M, Ali BH, et al. The influence of the prebiotic gum acacia on the intestinal microbiome composition in rats with experimental chronic kidney disease. Biomed Pharmacother. 2021;133:110992.
   PubMed Web of Science ®Google Scholar
• Perumal Samy R, Stiles BG, Sethi G, et al. Melioidosis: clinical impact and public health threat in the tropics. PLoS Negl Trop Dis. 2017;11(5):e0004738.
   PubMed Web of Science ®Google Scholar
• Xu H, Wang X, Feng W, et al. The gut microbiota and its interactions with cardiovascular disease. Microb Biotechnol. 2020;13(3):637–656.
   PubMed Web of Science ®Google Scholar
• Jin M, Qian Z, Yin J, et al. The role of intestinal microbiota in cardiovascular disease. J Cell Mol Med. 2019;23(4):2343–2350.
   PubMed Web of Science ®Google Scholar